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What is already known about this subject {#bcp14136-sec-0006}
========================================

Lidocaine is an effective anticonvulsant in neonates, but is also associated with cardiac toxicity.Several small studies have described lidocaine pharmacokinetics in various neonatal populations.Based on these studies, a lidocaine dosing regimen was developed for safe and effective lidocaine use.

What this study adds {#bcp14136-sec-0007}
====================

Lidocaine pharmacokinetics was described across the entire neonatal age range, with postmenstrual age and body temperature influencing lidocaine clearance.Evaluation of the previously developed dosing regimen shows that lidocaine can provide safe and effective treatment for neonatal seizures.

1. INTRODUCTION {#bcp14136-sec-0008}
===============

Neonatal seizures are signs of a serious neurological disorder in the neonatal period and are often caused by underlying brain pathology such as hypoxic--ischaemic encephalopathy (HIE), central nervous system infections or intracranial haemorrhage.[1](#bcp14136-bib-0001){ref-type="ref"}, [2](#bcp14136-bib-0002){ref-type="ref"}, [3](#bcp14136-bib-0003){ref-type="ref"} Neonatal seizures are associated with an increased risk of long‐term morbidity, including epilepsy and neurodevelopmental disorders possibly by adding damage to an already lesioned brain.[4](#bcp14136-bib-0004){ref-type="ref"}, [5](#bcp14136-bib-0005){ref-type="ref"}, [6](#bcp14136-bib-0006){ref-type="ref"}, [7](#bcp14136-bib-0007){ref-type="ref"}, [8](#bcp14136-bib-0008){ref-type="ref"} Therefore, effective treatment of seizures in neonates is important to prevent and reduce brain damage.[9](#bcp14136-bib-0009){ref-type="ref"}, [10](#bcp14136-bib-0010){ref-type="ref"}, [11](#bcp14136-bib-0011){ref-type="ref"}, [12](#bcp14136-bib-0012){ref-type="ref"}

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2623>, an amine derivative of <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2286>, is commonly used as a local anaesthetic and as a class 1b antiarrhythmic drug in both paediatric and adult patients.[13](#bcp14136-bib-0013){ref-type="ref"}, [14](#bcp14136-bib-0014){ref-type="ref"}, [15](#bcp14136-bib-0015){ref-type="ref"}, [16](#bcp14136-bib-0016){ref-type="ref"} However, it is also used as an anticonvulsant in neonates refractory to 1 or more other antiepileptic drugs (AEDs) such as phenobarbital and midazolam.[17](#bcp14136-bib-0017){ref-type="ref"} Lidocaine has proven to be effective in several observational studies in both term and preterm neonates and is favoured as a second‐ or third‐line anticonvulsant therapy in several European countries. The most important safety risk of the use of lidocaine is cardiac toxicity (bradycardia, arrhythmias or asystole), most likely to occur at plasma concentrations exceeding 9 mg/L.[18](#bcp14136-bib-0018){ref-type="ref"}, [19](#bcp14136-bib-0019){ref-type="ref"}, [20](#bcp14136-bib-0020){ref-type="ref"}, [21](#bcp14136-bib-0021){ref-type="ref"}, [22](#bcp14136-bib-0022){ref-type="ref"}

Lidocaine is metabolised in the liver by the <https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242>, predominantly by <https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1319> and to a lesser extent by <https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=263>. Monoethylglycinexylidide (MEGX) is the most prominent metabolite and is eliminated renally. Accumulation of MEGX has been associated with recurrent seizure activity.[23](#bcp14136-bib-0023){ref-type="ref"} An effect of gestational age (GA), postnatal age (PNA) and/or postmenstrual age (PMA) on the pharmacokinetics (PK) for lidocaine and MEGX can be expected given the physiological changes responsible for maturation of CYP1A2 and CYP3A activity as well as the development of renal function in neonates.[24](#bcp14136-bib-0024){ref-type="ref"}, [25](#bcp14136-bib-0025){ref-type="ref"}

Therapeutic hypothermia (TH), lowering the neonates\' core temperature to 33--34°C for 72 h is the standard of care for term and near term neonates (GA ≥ 36 weeks) with HIE to reduce the incidence of death and neurological disabilities.[26](#bcp14136-bib-0026){ref-type="ref"}, [27](#bcp14136-bib-0027){ref-type="ref"} This controlled hypothermia treatment can, however, have an additional effect on lidocaine clearance due to a possible reduction in organ perfusion and/or reduction in hepatic enzymatic activity secondary to TH.[28](#bcp14136-bib-0028){ref-type="ref"}, [29](#bcp14136-bib-0029){ref-type="ref"}, [30](#bcp14136-bib-0030){ref-type="ref"}, [31](#bcp14136-bib-0031){ref-type="ref"}, [32](#bcp14136-bib-0032){ref-type="ref"}

Previous studies from our group have investigated lidocaine PK in both preterm and term neonates with and without TH treatment. Lidocaine clearance was lower in preterm neonates compared to term neonates.[33](#bcp14136-bib-0033){ref-type="ref"} As GA in this population is closely related to body weight (BW), a novel dosing regimen differentiated by BW was proposed for safe (lidocaine plasma concentrations \<9 mg/L) and effective lidocaine use across the entire neonatal population (Table [1](#bcp14136-tbl-0001){ref-type="table"}). Compared to the previously used dosing regimens, the loading phase was reduced from 6 to 4 h.[18](#bcp14136-bib-0018){ref-type="ref"}, [33](#bcp14136-bib-0033){ref-type="ref"} In (near‐)term neonates, TH was found to reduce lidocaine clearance by 24% compared to normothermia. Therefore, a further reduction of the loading phase to 3.5 h during TH is incorporated in this dosing regimen.[34](#bcp14136-bib-0034){ref-type="ref"}

###### 

Proposed lidocaine dosing regimen[33](#bcp14136-bib-0033){ref-type="ref"}, [34](#bcp14136-bib-0034){ref-type="ref"}

                   Bolus     Loading phase   Maintenance phase I   Maintenance phase II                                   
  ---------------- --------- --------------- --------------------- ---------------------- ----------- ------ ------------ ------
  *Normothermia*                                                                                                          
  \< 1.6 kg        2 mg/kg   10 min          5 mg/kg               4 h                    2.5 mg/kg   12 h   1.25 mg/kg   12 h
  1.6--2.6 kg      2 mg/kg   10 min          6 mg/kg               4 h                    3 mg/kg     12 h   1.5 mg/kg    12 h
  \> 2.6 kg        2 mg/kg   10 min          7 mg/kg               4 h                    3.5 mg/kg   12 h   1.75 mg/kg   12 h
  *Hypothermia*                                                                                                           
  \< 2.5 kg        2 mg/kg   10 min          6 mg/kg               3.5 h                  3 mg/kg     12 h   1.5 mg/kg    12 h
  ≥ 2.5 kg         2 mg/kg   10 min          7 mg/kg               3.5 h                  3.5 mg/kg   12 h   1.75 mg/kg   12 h

However, we have only been able to investigate lidocaine PK in relatively small numbers of neonates and never simultaneously across the entire neonatal treatment spectrum. Furthermore, the effectiveness of the previously developed dosing regimen has not been evaluated.

The aim of the present study was, therefore, to evaluate the previously developed population PK models and proposed dosing regimen in a larger dataset encompassing preterm neonates and (near‐)term neonates with and without TH treatment. As a secondary objective, antiepileptic treatment effectiveness and the incidence of cardiac toxicity were assessed.

2. PATIENTS AND METHODS {#bcp14136-sec-0009}
=======================

2.1. Setting and study population {#bcp14136-sec-0010}
---------------------------------

For the current study, data collected in the multicentre prospective cohort SHIVER study[34](#bcp14136-bib-0034){ref-type="ref"} and from a historical dataset collected as part of routine clinical care[33](#bcp14136-bib-0033){ref-type="ref"} (both previously published) were combined with data collected from patients who were included in the multicentre prospective cohort PharmaCool study and a novel dataset collected for routine clinical care. The SHIVER study and the PharmaCool studies both included (near‐)term neonates treated with TH for HIE; neonates with congenital disorders were excluded. Full in‐ and exclusion criteria for both studies have been published previously.[35](#bcp14136-bib-0035){ref-type="ref"}, [36](#bcp14136-bib-0036){ref-type="ref"} Both studies were approved by the Ethics Committees of the participating centres and in both studies, written parental informed consent was obtained for each included neonate. The datasets collected during routine clinical care consisted of preterm and term neonates receiving lidocaine for treatment of neonatal seizures at the Neonatal Intensive Care Unit (NICU) of the University Medical Center Utrecht/Wilhelmina Children\'s Hospital between 2004 and 2018. An overview of the included neonates in the 2 studies and the 2 clinical care cohorts is shown in Table [2](#bcp14136-tbl-0002){ref-type="table"}.

###### 

Overview of the included neonates per study and cohort

                                                                  Time period   No. of patients                             Age groups, TH yes/no                          Dosing regimen(s)                                            Sampling
  --------------------------------------------------------------- ------------- ------------------------------------------- ---------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------
  Clinical care cohort 1                                          2004--2008    46                                          Preterm and term neonates, no TH               See[33](#bcp14136-bib-0033){ref-type="ref"}                  4--6 h and 10--12 h after start of lidocaine
  SHIVER study                                                    2008--2010    21[a](#bcp14136-note-0004){ref-type="fn"}   (Near‐)term neonates, all treated with TH      See[34](#bcp14136-bib-0034){ref-type="ref"}                  Once daily on days 2--5 after birth
  PharmaCool study[b](#bcp14136-note-0005){ref-type="fn"}         2010--2014    22                                          (Near‐)term neonates, all treated with TH      Various, none receiving the proposed dosing regimen          Once daily on days 2--5 after birth
  Clinical care cohort 2[b](#bcp14136-note-0005){ref-type="fn"}   2010--2018    70                                          Preterm and term neonates, 6 treated with TH   Various, 23 neonates receiving the proposed dosing regimen   Between 4‐6 h and between 10‐12 h after start of lidocaine

Abbreviation: TH = therapeutic hypothermia

one patient from in the SHIVER study was excluded because the exact timing of TH could not be retrieved.

included for assessment of effectiveness and safety.

2.2. Lidocaine dosing {#bcp14136-sec-0011}
---------------------

In all neonates, lidocaine was prescribed as second‐ or third‐line AED for seizures refractory to midazolam and/or phenobarbital. Lidocaine was administrated as continuous intravenous infusion according to local clinical protocols. In the SHIVER and PharmaCool studies, choice of therapy or dosing regimen was not influenced by the study protocol. Neonates in the second clinical care cohort received the proposed dosing regimen from 2015 onwards.

2.3. Sampling and bioanalysis {#bcp14136-sec-0012}
-----------------------------

In the SHIVER and PharmaCool studies, once daily blood samples were drawn on days 2--5 after birth. In the 2 clinical care cohorts, blood samples were drawn between 4 and 6 h and between 10 and 12 h after start of lidocaine administration. Plasma concentrations of lidocaine and MEGX in both studies and both cohorts were determined using a validated liquid chromatography--tandem mass spectrometric assay at the Clinical Pharmaceutical and Toxicological Laboratory of the Department of Clinical Pharmacy of the University Medical Center Utrecht, the Netherlands.[37](#bcp14136-bib-0037){ref-type="ref"} The lower limit of quantification (LLQ) for both lidocaine and MEGX was 0.2 mg/L.

2.4. Population PK analyses {#bcp14136-sec-0013}
---------------------------

PK analyses were performed using non‐linear mixed effects modelling NONMEM (version 7.3, Icon Development Solutions).[38](#bcp14136-bib-0038){ref-type="ref"} Lidocaine hydrochloride doses were converted to lidocaine base and consecutively, all units of dose and concentration for lidocaine and MEGX were converted to μmol and μmol/L, respectively for the purpose of the PK analysis. If the measured concentration for 1 of the compounds was below the LLQ, it was fixed to LLQ/2 (i.e. 0.1 mg/L for both compounds); samples with measurements below LLQ for both lidocaine and MEGX were excluded from analysis.[39](#bcp14136-bib-0039){ref-type="ref"} As the fraction (F) of lidocaine converted to MEGX was unknown, MEGX parameters were estimated relative to F. Based on the previous publications, a 1‐compartment model for lidocaine with a consecutive 1‐compartment model for MEGX were used as structural models.[33](#bcp14136-bib-0033){ref-type="ref"}, [34](#bcp14136-bib-0034){ref-type="ref"} BW was used as a descriptor for body size and was related to PK parameters using allometric relationships with an exponent of 0.75 on clearance and an exponent of 1 on volume of distribution.[40](#bcp14136-bib-0040){ref-type="ref"} GA, PNA, PMA and body temperature were tested as covariates on clearance. Body temperature was tested as a continuous variable using a dynamic model as described previously.[36](#bcp14136-bib-0036){ref-type="ref"} Inclusion of covariates was guided by effect size, biological plausibility and statistical significance.

Interindividual variability was modelled using a proportional model and tested on all parameters. To account for data below LLQ, both proportional and additive error models were used to model residual unexplained variability in which the additive error was fixed on LLQ/2. Separate error models were used for lidocaine and MEGX. Parameter precision was assessed with sampling importance resampling.[41](#bcp14136-bib-0041){ref-type="ref"} Both graphical (e.g. goodness‐of‐fit plots) and statistical model evaluation procedures were used to assess model adequacy.

2.5. Dosing regimen evaluation {#bcp14136-sec-0014}
------------------------------

To evaluate the previously developed dosing regimen, a simulation dataset was created by replicating the patient characteristics of each neonate included in the original dataset 7 times. The observed lidocaine plasma concentrations from neonates receiving the proposed dosing regimen were compared to the predicted lidocaine plasma concentrations using this simulation dataset and the parameter estimates from the PK model as reported by Van den Broek et al.[33](#bcp14136-bib-0033){ref-type="ref"} Additionally, simulations were conducted using the final parameter estimates from the PK model developed in this study and proposed dosing regimen. Mean peak lidocaine plasma concentrations \<9 mg/L were considered effective and safe. The peak lidocaine plasma concentration was established as the highest plasma concentration reached during lidocaine treatment. Additionally, accumulation of MEGX should be avoided to reduce the occurrence of adverse effects related to MEGX; however, an upper limit cannot be established based on literature.

2.6. Antiepileptic effectiveness and cardiac events {#bcp14136-sec-0015}
---------------------------------------------------

Antiepileptic effectiveness and incidence of cardiac events were assessed for neonates in the PharmaCool study and in the second cohort for clinical care as these have been published previously for the other datasets (Table [2](#bcp14136-tbl-0002){ref-type="table"}).[18](#bcp14136-bib-0018){ref-type="ref"}, [34](#bcp14136-bib-0034){ref-type="ref"} Lidocaine was considered effective for seizure control if no additional antiepileptic drug was needed after lidocaine therapy, including dose increases of AEDs started prior to lidocaine therapy. Incidence of cardiac toxicity such as bradycardia, arrhythmias or asystole was based on spontaneous reports by the local investigators or the treating physicians in the patient\'s study files or clinical care records.

2.7. Nomenclature of targets and ligands {#bcp14136-sec-0016}
----------------------------------------

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY.

3. RESULTS {#bcp14136-sec-0017}
==========

3.1. Patient characteristics {#bcp14136-sec-0018}
----------------------------

In total, 159 neonates were included in this study (SHIVER *n* = 21, PharmaCool *n* = 22, clinical care cohort 1 *n* = 46, clinical care cohort 2 *n* = 70, Table [2](#bcp14136-tbl-0002){ref-type="table"}). Fifty neonates (31.4%) were born prematurely (\<36 weeks GA) and 49 (30.8%) received TH (GA 36--42 weeks). Patient characteristics are presented in Table [3](#bcp14136-tbl-0003){ref-type="table"}. Lidocaine and/or MEGX plasma concentrations were determined in 444 samples.

###### 

Patient characteristics

  Parameter                                                         Patients (*n* = 159)
  ----------------------------------------------------------------- ----------------------
  Gestational age (weeks), mean ± SD                                37.0 ± 4.84
  Prematurity[a](#bcp14136-note-0007){ref-type="fn"}; *n* (%)       50 (31.4%)
  Body weight; kg, mean ± SD                                        2.89 ± 1.05
  Male; *n* (%)                                                     86 (54.1%)
  Treated with TH[b](#bcp14136-note-0008){ref-type="fn"}; *n* (%)   49 (30.8%)

Abbreviation: TH = therapeutic hypothermia

Neonates born with a gestational age \<36 weeks.

All neonates treated with TH were born with a gestation age ≥36 weeks

3.2. Population PK analyses {#bcp14136-sec-0019}
---------------------------

PkK parameter estimates of the final model are shown in Table [4](#bcp14136-tbl-0004){ref-type="table"}. GA but not PNA was identified as covariate for both lidocaine and MEGX clearance. However, combining GA and PNA into PMA as covariate on clearance for both compounds provided a better fit of the data. Average lidocaine clearance for a neonate of 3.5 kg at PMA 40 weeks was 1.77 L/h (95% confidence interval \[CI\] 1.63--2.03) whereas average lidocaine clearance for a neonate of 1 kg at PMA 25 weeks was 0.191 L/h (PMA effect 0.69%/day, 95% CI 0.54--0.84%). During TH, lidocaine clearance was reduced by 21.8% compared to normothermia (7.26%/°C, 95% CI 1.63--11.2%). No effect of TH on clearance of MEGX could be identified. Model evaluation demonstrated that the final models adequately described the data. Goodness‐of‐fit plots of observed *vs* population and individual predicted concentrations showed no systematic deviation and the weighted residuals were homogeneously scattered for both lidocaine and MEGX (Figures [S1](#bcp14136-supitem-0001){ref-type="supplementary-material"}--[S4](#bcp14136-supitem-0004){ref-type="supplementary-material"}).

###### 

Final model pharmacokinetic parameter estimates and SIR results

                                                            Lidocaine        MEGX[a](#bcp14136-note-0014){ref-type="fn"}                    
  --------------------------------------------------------- ---------------- --------------------------------------------- ---------------- ----------------
  Cl, l/h[c](#bcp14136-note-0016){ref-type="fn"}            1.77             1.63--2.03                                    1.51             1.37--1.73
  V, l[c](#bcp14136-note-0016){ref-type="fn"}               9.32             8.49--9.63                                    15.8             13.6--18.7
  PMA on Cl, %/d                                            0.690            0.581--0.837                                  0.350            0.114--0.805
  TEMP[d](#bcp14136-note-0017){ref-type="fn"} on Cl, %/°C   7.26             1.63--11.2                                    NA               NA
  *Interindividual variability*                                                                                                             
  Cl, variance (RSD)                                        0.231 (48.1%)    0.211--0.336                                  0.237 (48.7%)    0.148--0.368
  V, variance (RSD)                                         0.0673 (25.9%)   0.0365--0.0956                                0.478 (69.1%)    0.346--0.672
  *Residual variability*                                                                                                                    
  Additional, mg/L                                          0.1 (fixed)      NA                                            0.1 (fixed)      NA (fixed)
  Proportional, variance (RSD)                              0.0379 (19.5%)   0.0274--0.0431                                0.0550 (23.5%)   0.0445--0.0754

Final model:

Cl~LIDOCAINE~ = 1.77 × (BW/3.5)^0.75^ × (1 + 0.0069 × (PMA -- 280)) × (1 + 0.0726 × (TEMP‐36.5))

V~LIDOCAINE~ = 9.32 × (BW/3.5)^1^

Cl~MEGX~/F~MEGX~ = 1.51 × (BW/3.5)^0.75^ × (1 + 0.0035 × (PMA -- 280))

V~MEGX~/F~MEGX~ = 15.8 × (BW/3.5)^1^

MEGX estimates are relative to formation fraction F.

Ten iterations; no. of samples 1000, 1000, 1000, 1000, 1000, 1000, 2000, 2000, 2000, 2000; no. of resamples 200, 200, 400, 400, 500, 500, 1000, 1000, 1000, 1000.

Estimates for neonate with a birth weight of 3.5 kg and PMA 40 weeks.

In neonates treated with TH, TEMP was set to 33.5°C during TH with rewarming at 0.4°C/h. Normothermia for all neonates was set to 36.5°C.

Abbreviations: Cl = clearance; V = volume of distribution; PMA = postmenstrual age; TEMP = body temperature; SIR = sampling importance resampling; NA = not applicable; RSD = relative standard deviation; TH = therapeutic hypothermia; MEGX = monoethylglycinexylidide

3.3. Dosing regimen evaluation {#bcp14136-sec-0020}
------------------------------

Figure [1](#bcp14136-fig-0001){ref-type="fig"} shows that the observed lidocaine plasma concentrations from 22 normothermic neonates receiving the proposed dosing regimen were comparable to the predicted lidocaine plasma concentrations for normothermic neonates. Only 1 neonate received the proposed dosing regimen while treated with TH. Therefore, comparing the observed lidocaine plasma concentrations to the predicted range during TH was not sensible. Lidocaine plasma concentrations achieved with the proposed dosing regimen (Table [1](#bcp14136-tbl-0001){ref-type="table"}) were predicted using a simulation dataset of 1113 patients and the final PK parameter estimates. Both with and without TH, mean lidocaine peak plasma concentration was well below 9 ml/L (Figure [2](#bcp14136-fig-0002){ref-type="fig"}) and no accumulation of MEGX occurred. During normothermia, 20.0% of simulations reached a lidocaine plasma concentration above 9 mg/L (4.7% \>11 mg/L). During TH, lidocaine plasma concentrations exceeding 9 mg/L were reached in 31.8% of simulations (12.8% \>11 mg/L).

![Evaluation of the dosing regimen presented in Table [1](#bcp14136-tbl-0001){ref-type="table"} in 22 normothermic neonates. Black dots represent the observed lidocaine plasma concentrations. Solid line indicates the mean lidocaine plasma concentration and dark grey area represents the 95% prediction interval simulated with the final parameter estimates as reported by Van den Broek *et al* [33](#bcp14136-bib-0033){ref-type="ref"}](BCP-86-75-g001){#bcp14136-fig-0001}

![Simulated lidocaine and monoethylglycinexylidide plasma concentrations for normothermic (left) and hypothermic (right) neonates with the final parameter estimates obtained in this study and dosing regimen presented in Table [1](#bcp14136-tbl-0001){ref-type="table"}. Solid line indicates the mean lidocaine plasma concentration; dark grey area represents the 95% prediction interval. Dotted lines and light grey area indicate the mean MEGX plasma concentration and 95% prediction interval. horizontal dotted line indicates the suggested upper limit for lidocaine of 9 mg/L](BCP-86-75-g002){#bcp14136-fig-0002}

3.4. Antiepileptic effectiveness and cardiac events {#bcp14136-sec-0021}
---------------------------------------------------

Effectiveness and safety were assessed in 92 neonates. Overall, lidocaine was considered an effective anticonvulsant in 53.3% (49/92) of neonates. Of the 26 neonates without TH who were unresponsive to lidocaine 13 had meningitis, and 7 a major haemorrhage. Other diagnoses included asphyxia (4) GNAO1 mutation (1), and tuberous sclerosis (1). Lidocaine appeared to be most effective in term neonates not treated with TH. The predicted lidocaine plasma concentrations at the end of the loading phase did not differ between effective and ineffective treatment (Figure [3](#bcp14136-fig-0003){ref-type="fig"}). The proposed dosing regimen was administered to 23 neonates (25.0%). Within this subgroup, effectiveness was 56.5% (13/23) and lidocaine effectiveness appeared to be greater in (near‐)term neonates than in preterm neonates. Effectiveness with the previous dosing regimens was 52.2% (36/69). Lidocaine effectiveness is summarised in Table [5](#bcp14136-tbl-0005){ref-type="table"}. No cardiac adverse events were reported.

![Predicted lidocaine plasma concentrations at the end of the loading phase in neonates where lidocaine was effective (left) and ineffective (right). Horizontal lines represent the median plasma concentration; blue boxes represent the interquartile ranges; vertical lines indicate the highest and lowest plasma concentration](BCP-86-75-g003){#bcp14136-fig-0003}

###### 

Effectiveness of lidocaine as antiepileptic drug

                                    Effective, *n* (%)   Ineffective, *n* (%)
  --------------------------------- -------------------- ----------------------
  All patients (*n* = 92)           49 (53.3%)           43 (46.7%)
  *GA \<36 weeks (n = 28)*          *11 (39.3%)*         *17 (60.7%)*
  *GA ≥ 6 weeks, NT (n = 36)*       *27 (75.0%)*         *9 (25.0%)*
  *GA ≥ 6 weeks, TH (n = 28)*       *11 (39.3%)*         *17 (60.7%)*
  Novel dosing regimen (*n* = 23)   13 (56.5%)           10 (44.5%)
  *GA \<36 weeks (n = 6)*           *3 (50%)*            *3 (50%)*
  *GA ≥36 weeks (n = 17)*           *10 (58.8%)*         *7 (41.2%)*

Abbreviations: GA = gestational age, NT = normothermia, TH = therapeutic hypothermia

4. DISCUSSION {#bcp14136-sec-0022}
=============

This study successfully described lidocaine PK in a large dataset combining both preterm and term neonates with and without TH treatment. PMA and TH were identified as significant covariates on lidocaine clearance. The final parameter estimates for lidocaine clearance and volume of distribution obtained in this study are largely consistent with the previous findings, which confirms the previously identified PK parameters.[18](#bcp14136-bib-0018){ref-type="ref"}, [33](#bcp14136-bib-0033){ref-type="ref"}, [34](#bcp14136-bib-0034){ref-type="ref"} Evaluation of the proposed dosing regimen showed that average lidocaine plasma concentrations are well below the potential toxic upper limit of 9 mg/L for all neonates. Lidocaine effectiveness did not differ between the proposed and previous dosing regimens and no cardiac toxicity occurred.

Lidocaine is metabolised by the liver and its metabolites, including MEGX, are subsequently eliminated via the kidneys. PMA is identified as a covariate for maturation of both lidocaine and MEGX clearance. PMA was found to be a descriptor for maturation of morphine clearance, a hepatically cleared drug, by Knøsgaard et al.[42](#bcp14136-bib-0042){ref-type="ref"} and for glomerular filtration rate by Rhodin et al.[43](#bcp14136-bib-0043){ref-type="ref"} Both studies included data from neonates as well as older children and adults and incorporated PMA using a sigmoidal Hill equation. The TM~50~, the PMA at which clearance is 50% of the mature value, was estimated in both studies to be around 55 weeks. Our study was comprised of only neonatal data with a minimum PMA of 25 weeks and maximum PMA of 42.7 weeks. In this age range, the sigmoidal Hill equations approach linearity. Therefore, we decided to include PMA as a linear effect in this study.

TH reduced lidocaine clearance by 21.8% compared to normothermia. This is consistent with our findings in a previous study.[34](#bcp14136-bib-0034){ref-type="ref"} Lidocaine is qualified as a drug with a high hepatic extraction ratio, with hepatic perfusion as rate limiting step for metabolism.[44](#bcp14136-bib-0044){ref-type="ref"} During hypothermia, hepatic blood flow is decreased due to a decrease in cardiac output and stroke volume.[29](#bcp14136-bib-0029){ref-type="ref"}, [30](#bcp14136-bib-0030){ref-type="ref"}, [31](#bcp14136-bib-0031){ref-type="ref"}, [32](#bcp14136-bib-0032){ref-type="ref"} Therefore, we hypothesise that reduced blood flow during TH is primarily responsible for decreased lidocaine clearance. However, an additional or synergistic effect of TH on activity of CYP enzymes cannot be excluded based on this data. Renal perfusion is also dependent on cardiac output, but an effect of TH on clearance of MEGX has not been identified. Although an effect of TH on other renally cleared drugs and metabolites has been noted, this finding is consistent with the current knowledge regarding MEGX clearance.[34](#bcp14136-bib-0034){ref-type="ref"}, [36](#bcp14136-bib-0036){ref-type="ref"}, [45](#bcp14136-bib-0045){ref-type="ref"}, [46](#bcp14136-bib-0046){ref-type="ref"}

Simulations performed with the final PK estimates from the present study show that the proposed dosing regimen as depicted in Table [1](#bcp14136-tbl-0001){ref-type="table"} leads to acceptable average lidocaine plasma concentrations for both normothermic preterm and term neonates as well as term neonates treated with TH. The large interpatient variability will lead to plasma concentrations exceeding the supposed threshold for cardiac toxicity of 9 mg/L in some neonates for an acceptable period. Additionally, the proposed dosing regimen was validated by comparing the observed lidocaine plasma concentrations from neonates receiving this regime to the predicted concentrations based on the original PK model.[33](#bcp14136-bib-0033){ref-type="ref"} In 22 normothermic neonates the observed plasma concentrations fall largely within the predicted range. Unfortunately, this validation could not be performed for neonates treated with TH due to insufficient data.

Anticonvulsant effectiveness for lidocaine was assessed in 92 neonates in whom effectiveness was not reported previously. No relationship between effectiveness and lidocaine plasma concentrations at the end of the loading phase could be identified. This could be explained by the high heterogeneity in seizure aetiology in this population. Some neonates respond to lidocaine treatment while others are refractory to it, irrespective of the lidocaine plasma concentration. A higher lidocaine success rate was noted in (near‐)term neonates. This is consistent with a retrospective study with 413 term and preterm neonates where a significantly lower success rate was observed in preterm *vs* term neonates (55.3 *vs* 76.1%); overall antiepileptic effectiveness of lidocaine was 71.4%.[19](#bcp14136-bib-0019){ref-type="ref"} Seizure control in our study was lower but did not differ between the proposed and the old dosing regimen. In neonates treated with TH, however, lidocaine responds rate was markedly lower in the present study compared to Van den Broek et al. (39.3 *vs* 91%).[34](#bcp14136-bib-0034){ref-type="ref"} The majority of data on neonates treated with TH comes from the PharmaCool study (22/28, 78.6%). In the PharmaCool study, data were only collected for 5 days after birth which might have created a selection bias. As lidocaine was administered mostly as third‐line anticonvulsant after phenobarbital and midazolam in this population, only neonates who resorted to lidocaine treatment relatively early were included. It could be argued that these were neonates with more severe HIE unresponsive to any antiepileptic treatment. Mortality for neonates receiving lidocaine in the PharmaCool study was 77.3% (17/22), confirming the highly moribund prognosis. Additionally, Van den Broek et al.^34^ defined effectiveness as a reduction of electrographic seizure burden of \>80% within 4 h of commencing lidocaine instead of no need for additional anticonvulsants after lidocaine therapy and thus a shorter time frame for detecting treatment failure.

Cardiac toxicity was not seen in any neonate included in this study. Although lidocaine associated cardiac toxicity has been described, it is extremely rare and fatal incidents have only occurred when lidocaine was used concomitantly with phenytoin.[20](#bcp14136-bib-0020){ref-type="ref"}, [23](#bcp14136-bib-0023){ref-type="ref"}, [47](#bcp14136-bib-0047){ref-type="ref"}, [48](#bcp14136-bib-0048){ref-type="ref"} Lidocaine cardiac toxicity has been associated with plasma concentrations exceeding 9 mg/L. However, the relationship between toxicity and plasma concentration is based on anecdotal evidence in adults with coronary disease and might not be valid for neonates.[49](#bcp14136-bib-0049){ref-type="ref"}, [50](#bcp14136-bib-0050){ref-type="ref"} Additionally, neonates undergoing TH might be even less susceptible to cardiac side effects. Lidocaine inhibits <https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=579> on the cardiomyocyte, which are only available during the systolic phase.[34](#bcp14136-bib-0034){ref-type="ref"}, [51](#bcp14136-bib-0051){ref-type="ref"} During TH, the heart frequency is reduced compared to normothermia, thereby reducing the potential for cardiotoxicity. However, to minimise the chance of cardiac toxicity, lidocaine should not be co‐administered with phenytoin or to neonates with congenital heart disease.[22](#bcp14136-bib-0022){ref-type="ref"}

Possible limitations of this study are the lack of clinical precision in the diagnoses of efficacy as we could not incorporate electrographic confirmation of lidocaine (in)effectiveness. However, the use of (no) additional AEDs can be used as a surrogate marker for efficacy. Additionally, the incidence of cardiac adverse events in this study was based on spontaneous reports. This introduces a risk of bias due to underreporting. However, it is unlikely that any major cardiac event would have been omitted from the patient (study) records.

5. CONCLUSION {#bcp14136-sec-0023}
=============

This study describes lidocaine PK across the entire neonatal age range, with PMA and TH as significant covariates on clearance. The previously developed proposed dosing regimen leads to lidocaine plasma concentrations within the desired range with comparable effectiveness to the older regimens. No cardiac toxicity occurred. With the developed dosing regimen, lidocaine can be a safe and effective add‐on anticonvulsant in preterm and term neonates with and without TH.
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**FIGURE S1** Lidocaine goodness‐of‐fit plots for normothermic neonates (A) observed *vs* population predicted plasma concentrations; (B) observed *vs* individual predicted plasma concentrations; (C) population conditional weighted residuals *vs* population predicted plasma concentrations; (D) population conditional weighted residuals *vs* time after birth
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**FIGURE S2** Lidocaine goodness‐of‐fit plots for hypothermic neonates (A) observed *vs* population predicted plasma concentrations; (B) observed *vs* individual predicted plasma concentrations; (C) population conditional weighted residuals *vs* population predicted plasma concentrations; (D) population conditional weighted residuals *vs* time after birth
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**FIGURE S3** Monoethylglycinexylidide goodness‐of‐fit plots for normothermic neonates (A) observed *vs* population predicted plasma concentrations; (B) observed *vs* individual predicted plasma concentrations; (C) population conditional weighted residuals *vs* population predicted plasma concentrations; (D) population conditional weighted residuals *vs* time after birth
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**FIGURE S4** Monoethylglycinexylidide goodness‐of‐fit plots for hypothermic neonates (A) observed *vs* population predicted plasma concentrations; (B) observed *vs* individual predicted plasma concentrations; (C) population conditional weighted residuals *vs* population predicted plasma concentrations; (D) population conditional weighted residuals *vs* time after birth
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Click here for additional data file.
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